Skip to content

Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514122-23-00
Enrollment
22
Registered
2024-07-22
Start date
2021-10-07
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapy

Brief summary

Complete response rate (CR) as best response to treatment, defined according to the international Revised Response Criteria for Malignant Lymphoma . For patients with SMZL, response is defined according to Matutes et al. 2008 and for patients with gastric lymphomas, histological response is evaluated according to GELA scoring system

Detailed description

Adverse events type and severity according to CTCAE v5.0 and relationship to study treatment, Overall response rate (ORR), Progression free survival (PFS), Duration of response (DOR), Overall survival (OS)

Interventions

Sponsors

Association International Extranodal Lymphoma Study Group (IELSG)
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Complete response rate (CR) as best response to treatment, defined according to the international Revised Response Criteria for Malignant Lymphoma . For patients with SMZL, response is defined according to Matutes et al. 2008 and for patients with gastric lymphomas, histological response is evaluated according to GELA scoring system

Secondary

MeasureTime frame
Adverse events type and severity according to CTCAE v5.0 and relationship to study treatment, Overall response rate (ORR), Progression free survival (PFS), Duration of response (DOR), Overall survival (OS)

Countries

Austria, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026